Protective effect of DMPC, DMPG, DMPC/DMPG, LYSOPG and LYSOPC against drugs that cause channelopathies
First Claim
Patent Images
1. A composition consisting of:
- one or more pharmacologically active agents provided in an amount that induce a cardiac channelopathy or a condition resulting from the irregularity or alteration in the cardiac pattern selected from QTc, LQT2, LQTS, or torsades de pointes in a subject and one or more lipids provided in an amount sufficient to prevent or reduce the cardiac channelopathy or the condition resulting from the irregularity or alteration in the cardiac pattern caused by the one or more pharmacologically active agents in a formulation, wherein the formulation is dispersed in a pharmaceutically acceptable medium, solvent, or vehicle, wherein the active agent, the lipids, or both are dissolved, dispersed, or suspended in the medium, the solvent, or the vehicle, wherein the lipids reduce or prevent the cardiac channelopathy or a condition resulting from the irregularity or alteration in the cardiac pattern.
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention includes compositions and methods for preventing one or more cardiac channelopathies or conditions resulting from irregularities or alterations in cardiac patterns caused by an active agent or a drug in a human or animal subject comprising: an amount of a lysophosphatidylglycerol adapted for oral administration effective to reduce or prevent one or more cardiac channelopathies or conditions resulting from irregularities or alterations in cardiac patterns caused by the active agent or drug.
80 Citations
18 Claims
-
1. A composition consisting of:
one or more pharmacologically active agents provided in an amount that induce a cardiac channelopathy or a condition resulting from the irregularity or alteration in the cardiac pattern selected from QTc, LQT2, LQTS, or torsades de pointes in a subject and one or more lipids provided in an amount sufficient to prevent or reduce the cardiac channelopathy or the condition resulting from the irregularity or alteration in the cardiac pattern caused by the one or more pharmacologically active agents in a formulation, wherein the formulation is dispersed in a pharmaceutically acceptable medium, solvent, or vehicle, wherein the active agent, the lipids, or both are dissolved, dispersed, or suspended in the medium, the solvent, or the vehicle, wherein the lipids reduce or prevent the cardiac channelopathy or a condition resulting from the irregularity or alteration in the cardiac pattern. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8)
-
9. A composition consisting of:
one or more pharmacologically active agents provided in an amount that induce a cardiac channelopathy or a condition resulting from the irregularity or alteration in the cardiac pattern in a subject and one or more lipids provided in an amount sufficient to prevent or reduce the cardiac channelopathy or the condition resulting from the irregularity or alteration in the cardiac pattern caused by the one or more pharmacologically active agents in a formulation, wherein the formulation is dispersed in a pharmaceutically acceptable medium, solvent, or vehicle, wherein the active agent, the lipids, or both are dissolved, dispersed, or suspended in the medium, the solvent, or the vehicle, wherein the lipids form empty liposomes that reduce or prevent the cardiac channelopathy or a condition resulting from the irregularity or alteration in the cardiac pattern, wherein the active agent is selected from Albuterol, Alfuzosin, Amantadine, Amiodarone, Amisulpride, Amitriptyline, Amoxapine, Amphetamine, Anagrelide, Apomorphine, Arformoterol, Aripiprazole, Arsenic trioxide, Astemizole, Atazanavir, Atomoxetine, Azithromycin, Bedaquiline, Bepridil, Bortezomib, Bosutinib, Chloral hydrate, Chloroquine, Chlorpromazine, Ciprofloxacin, Cisapride, Citalopram, Clarithromycin, Clomipramine, Clozapine, Curcumin, Crizotinib, Dabrafenib, Dasatinib, Desipramine, Dexmedetomidine, Dexmethylphenidate, Dextroamphetamine, d-Amphetamine, Dihydroartemisinin and Piperaquine, Diphenhydramine, Disopyramide, Dobutamine, Dofetilide, Dolasetron, Domperidone, Dopamine, Doxepin, Dronedarone, Droperidol, Ephedrine, Epinephrine, Adrenaline, Eribulin, Erythromycin, Escitalopram, Famotidine, Felbamate, Fenfluramine, Fingolimod, Flecainide, Fluconazole, Fluoxetine, Formoterol, Foscarnet, Fosphenytoin, Furosemide, Frusemide, Galantamine, Gatifloxacin, Gemifloxacin, Granisetron, Halofantrine, Haloperidol, Hydrochlorothiazide, Ibutilide, Iloperidone, Imipramine, Melipramine, Indapamide, Isoproterenol, Isradipine, Itraconazole, Ivabradine, Ketoconazole, Lapatinib, Levalbuterol, Levofloxacin, Levomethadyl, Lisdexamfetamine, Lithium, Mesoridazine, Metaproterenol, Methadone, Methamphetamine, Methylphenidate, Midodrine, Mifepristone, Mirabegron, Mirtazapine, Moexipril/HCTZ, Moxifloxacin, Nelfinavir, Nicardipine, Nilotinib, Norepinephrine, Norfloxacin, Nortriptyline, Ofloxacin, Olanzapine, Ondansetron, Oxytocin, Paliperidone, Paroxetine, Pasireotide, Pazopanib, Pentamidine, Perflutren lipid microspheres, Phentermine, Phenylephrine, Phenylpropanolamine, Pimozide, Posaconazole, Probucol, Procainamide, Promethazine, Protriptyline, Pseudoephedrine, Quetiapine, Quinidine, Quinine sulfate, Ranolazine, Rilpivirine, Risperidone, Ritodrine, Ritonavir, Roxithromycin, Salbutamol, Salmeterol, Saquinavir, Sertindole, Sertraline, Sevoflurane, Sibutramine, Solifenacin, Sorafenib, Sotalol, Sparfloxacin, Sulpiride, Sunitinib, Tacrolimus, Tamoxifen, Telaprevir, Telavancin, Telithromycin, Terbutaline, Terfenadine, Tetrabenazine, Thioridazine, Tizanidine, Tolterodine, Toremifene, Trazodone, Trimethoprim-Sulfa, Trimipramine, Vandetanib, Vardenafil, Vemurafenib, Venlafaxine, Voriconazole, Vorinostat, and Ziprasidone. - View Dependent Claims (10, 11, 12, 13, 14)
-
15. A composition consisting of:
one or more pharmacologically active agents provided in an amount that induce a cardiac channelopathy or a condition resulting from the irregularity or alteration in the cardiac pattern selected from QTc, LQT2, LQTS, and torsades de pointes in a subject and one or more lipids provided in an amount sufficient to prevent or reduce the cardiac channelopathy or the condition resulting from the irregularity or alteration in the cardiac pattern caused by the one or more pharmacologically active agents in an intravenous formulation, wherein the formulation is dispersed in a pharmaceutically acceptable medium, solvent, or vehicle, wherein the active agent, the lipids, or both are dissolved, dispersed, or suspended in the medium, the solvent, or the vehicle, wherein the active agent is selected from Albuterol, Alfuzosin, Amantadine, Amiodarone, Amisulpride, Amitriptyline, Amoxapine, Amphetamine, Anagrelide, Apomorphine, Arformoterol, Aripiprazole, Arsenic trioxide, Astemizole, Atazanavir, Atomoxetine, Azithromycin, Bedaquiline, Bepridil, Bortezomib, Bosutinib, Chloral hydrate, Chloroquine, Chlorpromazine, Ciprofloxacin, Cisapride, Citalopram, Clarithromycin, Clomipramine, Clozapine, Curcumin, Crizotinib, Dabrafenib, Dasatinib, Desipramine, Dexmedetomidine, Dexmethylphenidate, Dextroamphetamine, d-Amphetamine, Dihydroartemisinin and Piperaquine, Diphenhydramine, Disopyramide, Dobutamine, Dofetilide, Dolasetron, Domperidone, Dopamine, Doxepin, Dronedarone, Droperidol, Ephedrine, Epinephrine, Adrenaline, Eribulin, Erythromycin, Escitalopram, Famotidine, Felbamate, Fenfluramine, Fingolimod, Flecainide, Fluconazole, Fluoxetine, Formoterol, Foscarnet, Fosphenytoin, Furosemide, Frusemide, Galantamine, Gatifloxacin, Gemifloxacin, Granisetron, Halofantrine, Haloperidol, Hydrochlorothiazide, Ibutilide, Iloperidone, Imipramine, Melipramine, Indapamide, Isoproterenol, Isradipine, Itraconazole, Ivabradine, Ketoconazole, Lapatinib, Levalbuterol, Levofloxacin, Levomethadyl, Lisdexamfetamine, Lithium, Mesoridazine, Metaproterenol, Methadone, Methamphetamine, Methylphenidate, Midodrine, Mifepristone, Mirabegron, Mirtazapine, Moexipril/HCTZ, Moxifloxacin, Nelfinavir, Nicardipine, Nilotinib, Norepinephrine, Norfloxacin, Nortriptyline, Ofloxacin, Olanzapine, Ondansetron, Oxytocin, Paliperidone, Paroxetine, Pasireotide, Pazopanib, Pentamidine, Perflutren lipid microspheres, Phentermine, Phenylephrine, Phenylpropanolamine, Pimozide, Posaconazole, Probucol, Procainamide, Promethazine, Protriptyline, Pseudoephedrine, Quetiapine, Quinidine, Quinine sulfate, Ranolazine, Rilpivirine, Risperidone, Ritodrine, Ritonavir, Roxithromycin, Salbutamol, Salmeterol, Saquinavir, Sertindole, Sertraline, Sevoflurane, Sibutramine, Solifenacin, Sorafenib, Sotalol, Sparfloxacin, Sulpiride, Sunitinib, Tacrolimus, Tamoxifen, Telaprevir, Telavancin, Telithromycin, Terbutaline, Terfenadine, Tetrabenazine, Thioridazine, Tizanidine, Tolterodine, Toremifene, Trazodone, Trimethoprim-Sulfa, Trimipramine, Vandetanib, Vardenafil, Vemurafenib, Venlafaxine, Voriconazole, Vorinostat, and Ziprasidone. - View Dependent Claims (16, 17, 18)
Specification
-
- Resources
Litigation Campaign Assessment
Thank you for your request. You will receive a custom alert email when the Litigation Campaign Assessment is available.
×
-
Current AssigneeSignPath Pharma, Inc.
-
Original AssigneeSignPath Pharma, Inc.
-
InventorsHelson, Lawrence
-
Primary Examiner(s)Roney, Celeste A
-
Application NumberUS15/347,381Publication NumberTime in Patent Office727 DaysField of SearchNoneUS Class CurrentCPC Class CodesA61K 2300/00 Mixtures or combinations of...A61K 31/445 Non condensed piperidines, ...A61K 31/506 not condensed and containin...A61K 31/683 Diesters of a phosphorus ac...A61K 31/685 one of the hydroxy compound...A61K 9/127 LiposomesG01N 2800/326 Arrhythmias, e.g. ventricul...G01N 33/5088 of vertebrates
